Objective:

To evaluate whether preoperative intranasal dexmedetomidine spray could alleviate perioperative anxiety and improve postoperative recovery quality in breast cancer patients undergoing modified radical mastectomy.

Approach:

Key Findings:

• Group D had a significantly lower PAS-7 score at 30 min compared to Group C (9.71 vs. 12.44, P < 0.001).
• QoR-15 scores were significantly higher in Group D at both 24 h (120.11 vs. 111.27, P < 0.001) and 48 h (127.04 vs. 123.20, P = 0.005) postoperatively.
• No significant differences were observed in AIS scores, intraoperative hemodynamic variables, anesthetic consumption, or vasoactive drug use.
• Time to emergence was significantly longer in Group D compared to Group C (8.36 vs. 6.36, P = 0.001).

Interpretation:

Preoperative intranasal dexmedetomidine spray alleviated preoperative anxiety and improved early postoperative recovery quality without significant adverse effects on intraoperative hemodynamics.

Limitations:

• The study was conducted at a single center, which may limit generalizability.
• The sample size was relatively small, consisting of only 90 patients.

Conclusion:

Preoperative intranasal dexmedetomidine spray is effective in reducing anxiety and enhancing recovery in breast cancer patients undergoing surgery, though it may prolong emergence time.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.